Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q1 FY26 results · Apr–Jun 2025
Gufic Biosciences reported revenue from operations of ₹223.72 crore (up 10.3% from Q1 FY25) and net profit of ₹13.07 crore (down 37.3% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 223.72 | 202.81 | +10.3% | 205.02 | +9.1% |
| Other income | 0.93 | 1.25 | −26.3% | 0.39 | +134.5% |
| Total income | 224.65 | 204.07 | +10.1% | 205.41 | +9.4% |
| Profit before tax | 17.27 | 28.10 | −38.5% | 10.52 | +64.1% |
| Net profit for the period | 13.07 | 20.86 | −37.3% | 7.72 | +69.3% |
| EPS, basic (₹) | 1.30 | 2.08 | −37.5% | 0.77 | +68.8% |
| Net margin (%) | 5.8 | 10.3 | 3.8 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 226.91 | 202.81 | +11.9% | 205.02 | +10.7% |
| Other income | 0.89 | 1.25 | −28.7% | 0.38 | +133.5% |
| Total income | 227.81 | 204.07 | +11.6% | 205.40 | +10.9% |
| Profit before tax | 16.28 | 28.11 | −42.1% | 10.78 | +51.0% |
| Net profit for the period | 12.07 | 20.86 | −42.1% | 7.97 | +51.4% |
| EPS, basic (₹) | 1.20 | 2.08 | −42.3% | 0.80 | +50.0% |
| Net margin (%) | 5.3 | 10.3 | 3.9 |
Consolidated
- Filed with BSE
- 13 Aug 2025, 20:29 IST
- Board meeting
- 13 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Aug 2025, 20:29 IST
- Board meeting
- 13 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE